Dr. Christopher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
# Div
Saint Louis, MO 63110Phone+1 314-454-8304Fax+1 314-454-5902
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2012 - 2016- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2010 - 2012
- Washington University in St. Louis School of MedicineClass of 2010
Certifications & Licensure
MO State Medical License 2013 - 2025
Clinical Trials
- Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Start of enrollment: 2021 May 20
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- IĸBζ as a Central Modulator of Inflammatory Arthritis Pathogenesis.Gaurav Swarnkar, Musarrat Naaz, Dorothy Mims, Prashant Gupta, Timothy Peterson
Arthritis & Rheumatology. 2024-09-15 - 12 citationsFlotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells.Joseph C Rimando, Ezhilarasi Chendamarai, Michael P Rettig, Reyka Jayasinghe, Matthew J Christopher
Blood. 2023-04-06 - 4 citationsDecitabine salvage for-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy.Francesca Ferraro, Agata Gruszczynska, Marianna B Ruzinova, Christopher A Miller, Mary Elizabeth Percival
Haematologica. 2022-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
